Biogen Inc. or Vericel Corporation: Who Invests More in Innovation?

Biogen's R&D spending dwarfs Vericel's by over 100 times.

__timestampBiogen Inc.Vericel Corporation
Wednesday, January 1, 2014189342200021263000
Thursday, January 1, 2015201280000018890000
Friday, January 1, 2016197330000015295000
Sunday, January 1, 2017225360000012944000
Monday, January 1, 2018259720000013599000
Tuesday, January 1, 2019228060000030391000
Wednesday, January 1, 2020399090000013020000
Friday, January 1, 2021250120000016287000
Saturday, January 1, 2022223110000019943000
Sunday, January 1, 2023270260000021042000
Loading chart...

Infusing magic into the data realm

Biogen Inc. vs. Vericel Corporation: A Decade of Innovation Investment

In the competitive landscape of biotechnology, innovation is the lifeblood of progress. Over the past decade, Biogen Inc. and Vericel Corporation have demonstrated contrasting approaches to research and development (R&D) investments. Biogen, a leader in neurological therapies, has consistently outpaced Vericel, a specialist in advanced cell therapies, in R&D spending. From 2014 to 2023, Biogen's R&D expenses averaged nearly 2.4 billion annually, peaking in 2020 with a staggering 4 billion, reflecting a robust commitment to innovation. In contrast, Vericel's annual R&D investment averaged around 18 million, with a notable increase in 2019. This disparity highlights Biogen's aggressive strategy, investing over 100 times more than Vericel in certain years. As the biotech industry evolves, these investment patterns may shape the future breakthroughs and market leadership of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025